The aim of this study was to determine, in an animal model, the effects of tadalafil on myocardial infarct size (IS), hemodynamics and regional myocardial blood flow after myocardial ischemia and reperfusion. Patients with erectile dysfunction (ED) often have risk factors for coronary artery disease. Tadalafil, a long-acting inhibitor of the enzyme phosphodiesterase-5 (PDE5), is used for the treatment of ED; there are no previous data regarding tadalafil in the setting of coronary artery occlusion (CAO). Sprague-Dawley male rats were treated with tadalafil or vehicle (10 mg/kg, by gastric gavage), 2 h before a 30 min CAO. Heart rate was comparable between tadalafil and control groups. Tadalafil reduced mean arterial pressure (P ¼ 0.009), systolic (P ¼ 0.035) and diastolic (P ¼ 0.009) blood pressures during ischemia/reperfusion. Tadalafil significantly reduced IS (4272%) versus controls (5473%) (P ¼ 0.006). For the first time, we showed that the PDE5 inhibitor, tadalafil, was well tolerated and cardioprotective in the setting of an experimental myocardial infarction, by substantially reducing ischemic cell death.
Introduction
Tadalafil (Cialis) is an inhibitor of the enzyme phosphodiesterase-5 (PDE5), a class of mild vasoactive drugs developed for the treatment of erectile dysfunction (ED); the other available PDE5 inhibitors are sildenafil citrate (Viagra) and vardenafil HCl (Levitra). ED is a common disorder that affects almost 200 million men worldwide. 1, 2 Studies have shown that vascular endothelial dysfunction is a main cause of ED, thus suggesting that ED might be an early manifestation of cardiovascular disease. 3, 4 Indeed, patients with ED have many of the risk factors associated with coronary artery disease (CAD), such as smoking, hypertension, diabetes and hyperlipidemia. 1, 5 The association between ED and CAD has raised concern regarding the cardiovascular safety of PDE5 inhibitors. PDE5 catalyzes the breakdown of the potent smooth muscle-relaxing agent cyclic guanosine monophosphate (cGMP), a second messenger of nitric oxide. Inhibition of PDE5 increases cGMP levels, reduces intracellular calcium and induces vasodilation. 6 So far, clinical studies have shown that PDE5 inhibitors are safe and do not increase cardiovascular risk in patients with CAD. [7] [8] [9] Recent studies have shown that these medicines improve endothelial function and may also have vascular and myocardial protective effects. [10] [11] [12] [13] Tadalafil differs from sildenafil and vardenafil by its pharmacokinetic profile, 17.5 h half-life, maximum plasma concentration at 2 h and efficacy for up to 36 h after dosing. 14 As there is no previous information on tadalafil in the setting of myocardial infarction, we studied the effects of tadalafil on infarct size (IS), hemody-namics and regional myocardial blood flow (RMBF) after myocardial ischemia and reperfusion. 15, 16 As studies on sildenafil have implicated the mitochondrial ATP-sensitive K (mK ATP ) channels in the cardioprotective effect of the drug, we also investigated whether tadalafil's protective effects on the heart occur through an mK ATP channel mechanism. 10, 13 Materials and methods 
Animals

Treatment
Rats were randomized to receive tadalafil or vehicle (control group) at the dose of 10 mg/kg, which was indicated by Lilly ICOS LLC (Bothell, WA, USA). The treatment was given by gastric gavage 2 h before coronary artery occlusion (CAO). Another group of animals treated with tadalafil or vehicle also received 5 mg/kg of the selective blocker of mK ATP channel, 5-hydroxydecanoate (5-HD), 10 min before CAO. The study was conducted in a blinded manner, with solutions provided in bottles labeled with a secret code by Lilly ICOS LLC. Both tadalafil and vehicle (hydroxypropyl methylcellulose phthalate) were formulated in 1% hydroxypropyl methylcellulose/1% Tween 80.
Acute myocardial infarction
The rats were anesthetized with intraperitoneal injection of 75 mg/kg ketamine and 5 mg/kg xylazine, endotracheally intubated and ventilated with a rodent respirator. A temperature probe was inserted into the rectum to monitor body/rectal temperature, maintained at 361C with a heating pad. A cut-down was made in the neck to expose the carotid artery and the jugular vein and fluid-filled catheters were inserted into the vessels.
A thoracotomy was performed in the fourth left intercostal space and the pericardium removed. A suture was placed under the proximal portion of the left coronary artery, the ends of the suture were threaded through a piece of plastic tubing, forming a snare that when tightened and clamped occluded the artery. The coronary artery was occluded for 30 min, and then reperfused (by releasing the clamp) for 3 h. At the end of the reperfusion phase, the artery was reoccluded and 0.8 ml of 50% Unisperse blue pigment suspension (Ciba-Geigy, Hawthorne, NY, USA) was injected via the jugular vein, to identify the ischemic risk area (not perfused by the blue dye). While the rats were deeply anesthetized, 2 ml of potassium chloride (2 mEq/ml) was injected into the same vein to stop the heart in diastole and the heart was excised.
Hemodynamics
Heart rate (HR), mean arterial pressure (MAP), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured through a pressure transducer connected to the catheter inserted into the carotid artery (ADInstruments, Colorado Springs, CO, USA) and recorded at different time points in the course of the experiment. Episodes of arrhythmias, if manifested (based on HR and blood pressure tracings), were also recorded. RMBF RMBF was assessed by using 1 Â 10 6 radioactive microspheres labeled with 141 Ce or 103 Ru (PerkinElmer Life Sciences, Boston, MA, USA). RMBF was measured twice, at 25 min of CAO and at the end of reperfusion, by injecting 0.5 ml of sucrose solution containing the microspheres into the left ventricle (LV) and by simultaneously withdrawing a reference blood sample from the carotid artery at a rate of 0.37 ml/min.
Post-mortem evaluation
The excised hearts were cleared of the right ventricle and sliced into five transverse sections from apex to base, which were weighed and photographed to identify the non-perfused region or area at risk (AR). The slices were then incubated in a 1% solution of triphenyltetrazolium chloride at 371C for 15 min, kept in formalin overnight and rephotographed the following morning to demonstrate the necrotic area. Computerized planimetry of the photographs was used to determine the AR and of necrosis (AN), expressed as % of LV, which were used to calculate the IS, expressed as % of AR (IS ¼ necrosis/risk Â 100).
Measurement of RMBF
Samples from infarcted and non-infarcted areas were dissected from the heart slices and weighed. The radioactivity of these tissue samples and the reference blood sample were counted in a gamma counter and RMBF was calculated. 
Results
Effects of tadalafil after myocardial ischemia/ reperfusion Hemodynamics. There were no significant differences in HR between tadalafil (n ¼ 15) and control (n ¼ 15) groups either at baseline or during occlusion or reperfusion ( Figure 1 ). Tadalafil reduced MAP, SBP and DBP throughout the experiment (P ¼ 0.009, P ¼ 0.035 and P ¼ 0.009, respectively) ( Figures 2 and 3) . In both groups, MAP, SBP and DBP were significantly lower during the occlusion and reperfusion phases than at baseline (Po0.001, P ¼ 0.026 and Po0.001, respectively). There were no differences in the frequency of arrhythmias between the two groups.
RMBF. Either during occlusion or during reperfusion, RMBF in the ischemic area was lower than that in the non-ischemic area (Table 1) . However, there were no significant differences in RMBF values between the two groups in each area (Table 1) .
Infarct size. Planimetric analysis showed that the ischemic AR (% of LV) was not significantly different between the two groups ( Table 1) . IS (% of AR) was decreased significantly in the tadalafil group (4272%) compared to controls (5473%) (P ¼ 0.006). Correlation between AR and AN in the tadalafil versus control group showed that for any AR, rats treated with tadalafil had smaller percentage of necrosis (P ¼ 0.004; Figure 4 ).
Did tadalafil act through an mK ATP channel mechanism? Hemodynamics and RMBF. The two groups, tadalafil þ 5-HD (n ¼ 10) and control þ 5-HD (n ¼ 6), showed no significant differences in HR, MAP, SBP, DBP, frequency of arrhythmias and RMBF (data not shown).
Infarct size. The two groups had similar AR: tadalafil þ 5-HD, 3571%; control þ 5-HD, 3573%; AN was 1871% in the tadalafil þ 5-HD group; and 2272% in the control þ 5-HD group. IS (% of AR) was significantly smaller in the tadalafil þ 5-HD group (5273%) compared to control þ 5-HD (6271%) (P ¼ 0.003). Tadalafil reduces myocardial infarct size C Sesti et al Figure 5 shows the AR/AN correlation for all the four groups: tadalafil, control, tadalafil þ 5-HD and control þ 5-HD. It is evident that for any AR, tadalafil-treated rats have the smallest and control þ 5-HD rats the biggest percentage of necrosis. It also shows how the lines of regression of control and tadalafil þ 5-HD groups are very close; in fact, the IS are very similar (54 and 52%, respectively). Tadalafil reduces myocardial infarct size C Sesti et al
Discussion
In this study, we showed that the PDE5 inhibitor tadalafil reduced myocardial IS in a rat model of myocardial ischemia without having unsafe hemodynamic effects that might increase oxygen demand. Tadalafil induced an expected small reduction in arterial pressure, did not cause a coronary artery steal phenomenon and was not associated with arrhythmias during coronary occlusion.
Tadalafil is the most recently approved PDE5 inhibitor used for the treatment of ED. A significant percentage of men with ED also suffer from cardiovascular disease and men with increased cardiovascular risk have a higher incidence of ED. 1, 5 Because of this correlation between ED and cardiovascular disease, and because tadalafil has a half-life of 17.5 h, it would be important to know what effect tadalafil might have in men who develop myocardial ischemia or infarction while this medicine is 'on board'. By inhibiting PDE5, tadalafil induces accumulation of cGMP, resulting in dilatation of blood vessels and decrease in blood pressure. The theoretical concern is that the drop in blood pressure could exacerbate ischemia and infarction in men with severely obstructed vessels, as in this case myocardial blood flow is dependent on perfusion pressure. A second theoretical concern with any vasodilator is that there will be a coronary artery steal phenomenon, whereby coronary flow will be diverted through collaterals from the ischemic coronary bed to the non-ischemic bed -another potential mechanism for worsening ischemia.
To date, no one has investigated the effects of tadalafil on IS and hemodynamics in a myocardial ischemia model. In our study, we determined what happens during myocardial infarction when this drug is present by examining the effects of tadalafil on myocardial IS, hemodynamics and RMBF in a rat model of coronary ischemia/reperfusion. Our data showed that the size of the myocardial infarct was significantly reduced after tadalafil treatment, and that for any AR, rats treated with tadalafil had a smaller percentage of necrosis. We cannot draw the Tadalafil reduces myocardial infarct size C Sesti et al conclusion that the mK ATP channels are involved in the tadalafil effect on myocardial IS in our study, because the vehicle þ 5-HD group had an IS bigger than the group treated with vehicle alone; thus suggesting that 5-HD by itself might have a negative effect on IS in this model. Whereas the involvement of the mK ATP channels has been demonstrated for the cardioprotective effect of sildenafil, the possibility of the same mechanism of action being involved for the tadalafil effect, at least in view of our results, will require further investigation. 10, 13 It has been suggested that elevated levels of cGMP, caused by PDE5 inhibitors, could inhibit PDE3, an enzyme responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP) and increase cAMP levels, resulting in elevated HR and contractility. 19 Our results showed that tadalafil did not increase HR nor induce arrhythmias.
As expected from a PDE5 inhibitor, tadalafil induced a moderate reduction in MAP, SBP and DBP during ischemia/reperfusion. Other studies have reported that sildenafil and vardenafil also cause a small drop in SBP and DBP. 7 The reason is that PDE5 is found not only in smooth muscle cells of the vasculature of the corpus cavernosum but also in smooth muscle cells of arteries and veins systemically. There were also no differences in RMBF between tadalafil and control rats, suggesting coronary steal did not occur.
Tadalafil has been shown to improve erectile function in a broad population of men with ED and in men with ED and comorbid conditions (cardiovascular disease, hypertension, diabetes, depression, hyperlipidemia) or after prostatectomy. 20, 21 The incidence of cardiovascular adverse events was not found higher in patients receiving tadalafil and cardiac mortality in tadalafil-treated patients was similar to that expected in the general male population. [7] [8] [9] 15 Sildenafil has been shown to be beneficial in pulmonary hypertension and cardiac hypertrophy. 22, 23, 12 Tadalafil and sildenafil have also been shown to improve endothelial dysfunction in patients with high cardiovascular risk, chronic heart failure, diabetes and in smokers. 11, [24] [25] [26] There is evidence that PDE5 inhibitors may have cardioprotective effects. Kukreja and associates have shown that sildenafil induced cardioprotection by reducing IS in an ischemia/reperfusion rabbit model. 13 Our research group has also investigated the cardiovascular effects of sildenafil, and observed other positive effects, such as reduction of LV diastolic pressure during occlusion, improvement of myocardial blood flow in the reperfused myocardium and no increase in arrhythmias. 27 In conclusion, the present study, which was the first to investigate the effect of tadalafil in an experimental model of myocardial infarction, showed that the moderate vasodilation induced by tadalafil could be potentially beneficial in the setting of ischemic heart disease. Our findings demonstrated that the PDE5 inhibitor, tadalafil, was well tolerated in an experimental model of coronary occlusion, as indicated by no evidence for increase in HR, arrhythmias or coronary steal. In addition, tadalafil was cardioprotective, as revealed by a significant reduction of ischemic cell death in the setting of acute CAO. Tadalafil reduces myocardial infarct size C Sesti et al
